Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
BioNTech losses more-than-quadruple in second quarter
(Sharecast News) - German pharmaceutical company BioNTech reported a sharp increase in losses for its second quarter on Monday, as it pivoted away from its Covid-19 vaccine business towards cancer drug development. The company revealed a net loss of €807.8m for the quarter - significantly wider than the €190.4m loss recorded in the same period last year.
It said a decline in Covid-19 vaccine sales played a major role in the financial downturn, with overall quarterly revenue falling 23% to €128.7m.
BioNTech's Covid-19 vaccine, developed in collaboration with Pfizer, had been a major revenue driver during the pandemic, but demand had since waned.
In response, BioNTech said it was reallocating resources, with 90% of its research and development budget now focussed on non-Covid projects, particularly in oncology and mRNA technologies.
The company said it planned to launch its first cancer treatment by 2026.
"The year to date has been marked by significant data updates across our oncology portfolio," said co-founder and chief executive officer Ugur Sahin.
"These readouts reinforce the potential of our platform technologies including our individualised and off-the-shelf mRNA vaccine platforms, iNeST and FixVac.
"We have also advanced our strategy by initiating clinical trials evaluating novel combinations of synergistic drug candidates."
Dr Sahin noted that the company dosed the first patient in a trial evaluating the combination of the TROP2 antibody-drug conjugate BNT325/DB-1305 and the PD-L1-VEGF-A bispecific BNT327/PM8002, aiming to harness the "potent" anti-tumour activity of antibody drug conjugates along with the sustained benefit of immunomodulators,.
"In addition, we have started commercialising variant-adapted Covid-19 vaccines for the upcoming season, while accelerating our clinical development efforts to realise the full potential of our technologies.
"We are making progress towards our goal of becoming a company with marketed medicines for cancer and infectious diseases."
At 1458 CEST (1358 BST), shares in BioNTech were down 5.8% at €69.90.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.
